Clear cell renal cell carcinoma (ccRCC) is a common urological malignancy. Key to the management of patients with ccRCC is identification of novel biomarkers and investigation of the underlying mechanism of the development of ccRCC. Thymosin b10 (TMSB10) is a member of the thymosin family and is involved in several physiological processes such as tissue regeneration and inflammatory regulation. TMSB10 has been found to be upregulated in many types of carcinoma.
According to Qiufeng Pan and colleagues in China, the roles of TMSB10 in ccRCC is unknown. The researchers conducted a study to examine the expression of TMSB10 in ccRCC and to investigate the association between TMSB10 expression and clinicopathological factors. Results of the study were reported in the International Journal of Oncology [doi.org/10.3892/ijo.2020.4991].
The study utilized The Cancer Genome Atlas and Oncomine databases; TMSB10 expression in human ccRCC tissues and cell lines was verified via immunohistochemistry assays and western blotting; the roles of TMSB10 in vitro were identified using functional analyses.
Results of the study showed a close association between TMSB10 and various clinicopathological parameters. Further, high expression of TMSB10 was a predictor of poor clinical outcome. The receiver operating characteristic curve demonstrated that TMSB10 could sufficiently distinguish between the tumor from normal kidney (area under the curve=0.9543; P<0.0001).
Knockdown of TMSB10 impaired the proliferation of ccRCC cells, and attenuated cell and invasion in vitro. TMSB10 knockdown also reduced the phosphorylation of P13K and the expression of vascular endothelial growth factor.
“In conclusion, the present study demonstrated that high expression of TMSB10 could serve as a useful diagnostic and prognostic biomarker and a potential therapeutic target for ccRCC,” the researchers said.